A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATION OF INTRAVENOUS AND ORAL CAPSULE FORMULATIONS IN HEALTHY MALE AND FEMALE SUBJECTS
Doctors are studying a new medication called velusetrag. This research is a very early stage study to understand how our bodies handle this medicine. They want to see how much of the medicine gets absorbed when taken as a capsule by mouth, compared to when it's given directly into the bloodstream through a drip. They also want to know how quickly these different forms of the medicine are processed and leave the body. This information is important for potentially treating conditions like chronic intestinal pseudo-obstruction (CIPO), but this specific study is focused on healthy adult volunteers to get a basic understanding of the drug's behaviour.
At a glance
What is this study about?
This study is about a new medicine called velusetrag. It's a very early-stage study, often called 'Phase I', meaning it's one of the first times this medicine is being tested in people. The main goal is to understand how your body handles the medicine.
Specifically, researchers want to see how the medicine acts when you take it in two different ways: as a capsule by mouth, and when it's given directly into your bloodstream through a drip (intravenous). They will measure how much of the medicine actually gets into your system and how long it stays there. This is important because it helps scientists understand the best way to give the medicine in the future.
While this medicine is being developed for conditions like chronic intestinal pseudo-obstruction (CIPO), this particular study involves healthy adult volunteers. By studying healthy people first, doctors can learn how the medicine naturally behaves in the body before testing it in patients who are unwell. This helps ensure the medicine is as safe as possible and works as expected.
Key takeaways
- This is an early study to understand how a new medicine, velusetrag, works in the body.
- It's for healthy adult volunteers, both men and women, aged 18 and over.
- The study compares taking the medicine by mouth (capsule) versus through a drip (IV).
- It aims to find out how well the medicine is absorbed and how long it stays in the body.
- Your participation helps doctors learn more about the medicine for future use in conditions like CIPO.
- You can stop participating at any time.
Who may be eligible?
This study is looking for healthy adult volunteers, both men and women, who are aged 18 or older. There is no upper age limit for taking part.
Because this is a very early study to understand how a new medicine works, participants need to be generally well and not have any serious health conditions that might affect how the medicine acts in their body.
More detailed checks will happen before anyone can join, to make sure it's safe for them and that the study results will be clear. For example, they will check your general health, any medicines you take, and if you have certain medical histories.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Are you able to attend several clinic visits?
- Are you comfortable with having blood tests?
- Are you happy to stay overnight in a clinic if required?
What does participation involve?
Taking part in this study would involve several visits to a clinic. You would receive the study medicine, velusetrag, on separate occasions: once as an oral capsule (by mouth) and another time through an intravenous drip (into your arm). Researchers would take blood and urine samples regularly after each dose to measure how the medicine is processed by your body. You would also have check-ups to monitor your overall health and any side effects. Each dosing period would likely involve an overnight stay or extended stay at the clinic. The total time you would be involved in the study, including follow-up visits, would be explained in full detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is chronic intestinal pseudo-obstruction (CIPO)?
CIPO is a rare and serious condition where your gut doesn't move food along properly, similar to a blockage, but there isn't an actual physical blockage.
Why are you studying healthy people if this medicine is for a gut condition?
Early studies like this are done in healthy volunteers first to safely understand how the medicine behaves in the body before testing it in people who are already unwell. This helps doctors figure out the right doses and how often to give the medicine.
Will I get the actual medicine or a dummy pill?
In this specific study, all participants will receive the active medicine, velusetrag, at different times, both as a capsule and through a drip. No dummy pills (placebo) are used in this early stage of research.
What kind of tests will I have?
You will mostly have blood tests to measure the medicine's levels in your body, and possibly urine tests. You'll also have regular check-ups to make sure you are feeling well.
Will I be paid for taking part?
Many clinical trials offer payment for your time and to cover expenses like travel. This will be discussed in detail by the study team.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.